Thu. Oct 6th, 2022


“The increase in Bronchopulmonary Dysplasia Market size is a direct consequence of an increase in R&D activity, increasing prevalent population, expected commercial success of upcoming therapies in the 7MM”


The potential drugs recently launched in the Bronchopulmonary Dysplasia Market or expected to get launched in the market during the study period 2019-2032


Bronchopulmonary Dysplasia Market Research Report is a comprehensive analysis of the study of Healthcare industry. DelveInsight included in this report emerging drugs, market drivers, market barriers, unmet medical needs, market share, and market size from 2019 to 2032 which is segmented by seven major markets.

Key takeaways from the Bronchopulmonary Dysplasia Market Research Report

  • According to DelveInsight, the Bronchopulmonary Dysplasia Market in 7MM is expected to witness a major change in the study period 2019-2032
  • DelveInsight’s assessment based on the recent studies suggests that overall 69% of the cases belong to EU5 in 7 major markets for the study period, 2017.
  • As per DelveInsight estimates, the total cases of Bronchopulmonary Dysplasia (BPD) in the 7MM was found to be 64,468 in 2017. Among all the countries, the estimates show a higher population of BPD in the United States in 2017.
  • The Bronchopulmonary Dysplasia occurrence has considerably upturned in the past few decades, due to increased pre-term birth cases and their improved survival rates of very low birth infants with support of mechanical ventilation.
  • Bronchopulmonary Dysplasia companies such as Medipost, Windtree Therapeutics, Therabron Therapeutics, Shire/ Takeda, and several others.
  • Bronchopulmonary Dysplasia drugs/therapies such as PNEUMOSTEM, AEROSURF, CG100, SHP607, and several others.

Get an Exclusive Sample Copy of the Report Here- Bronchopulmonary Dysplasia Market Share

Bronchopulmonary Dysplasia Overview

Bronchopulmonary Dysplasia is defined as the need for increased oxygen in infants: <32 weeks gestation: oxygen requirement at 36 weeks gestational age (GA) or at discharge (whichever comes first), ≥32 weeks GA: oxygen requirement at age >28 d or at discharge (whichever comes first). It applied the clinical criteria from both 28 days of oxygen need and an assessment of respiratory support at 36 weeks’ post menstrual age (PMA).

Bronchopulmonary Dysplasia Epidemiology Segmentation in the 7MM

  • Bronchopulmonary Dysplasia Preterm and Early Preterm Cases
  • Total Bronchopulmonary Dysplasia Cases
  • Bronchopulmonary Dysplasia Severity Specific Cases
  • Bronchopulmonary Dysplasia Diagnosed and Treatable cases

Bronchopulmonary Dysplasia Treatment Market

Bronchopulmonary Dysplasia Treatment is conceptualized into three stages; prevention of BPD, treatment of evolving BPD, and established Bronchopulmonary Dysplasia. Antenatal care is mainly used to reduce preterm birth, which would significantly impact the incidence of BPD. Neonatal resuscitation with good airway management, initial mask ventilation with the lowest possible inflation pressures, and the use of pressure limited devices, with initial respiratory support and fluid, and nutrition management along with surfactant treatment are helpful.

The treatment of evolving BPD includes ventilation, early postnatal corticosteroids, and macrolide antibiotics. Oxygen therapy is one of the mainstays in the management of infants at high risk for or with established Bronchopulmonary Dysplasia. Diuretics, bronchodilators, and corticosteroids (inhaled and systemic) are frequently used in infants with established BPD. Supportive therapies including the increased use of non-invasive ventilation and careful oxygen delivery strive to reduce injury inflicted on the developing lung.

For further information on the Market Impact of therapies, download Bronchopulmonary Dysplasia Market Sample @ Bronchopulmonary Dysplasia Market Outlook

“As per DelveInsight assessments, the Bronchopulmonary Dysplasia market size in the 7MM was found to be highest in the United States in 2017”

Bronchopulmonary Dysplasia Market Size

Among 7MM, EU5 accounts for the highest market size of Bronchopulmonary Dysplasia (BPD) in comparison with the US and Japan. EU5 has occupied more than 60% of the market share for the BPD, in the total 7MM. Among EU5 countries, the UK had the highest market size, while Germany had the lowest market size of BPD in 2017.

Bronchopulmonary Dysplasia Therapeutics Market

The upcoming therapy market is expected to be dominated by stem cell therapies with mesenchymal stromal cells and synthetic surfactant therapies, and recombinant proteins. With all these efforts, the market is expected to grow by providing better and long-term treatment options such as, PNEUMOSTEM (Medipost), AERO SURF (Windtree Therapeutics), CG100 (Therabron Therapeutics), and SHP607 (Shire/ Takeda), which are expected to enter the market by forecast period (2020–2030). Post-2021, the market is expected to witness rapid growth due to the increased awareness/screening programs and the launch of emerging therapies.

Discover more about therapy set to grab substantial Bronchopulmonary Dysplasia market landscape @ Bronchopulmonary Dysplasia Market Landscape

Scope of the Bronchopulmonary Dysplasia Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Forecast Period- 2022-2032
  • Bronchopulmonary Dysplasia companies such as Medipost, Windtree Therapeutics, Therabron Therapeutics, Shire/ Takeda, and several others.
  • Bronchopulmonary Dysplasia drugs/therapies such as PNEUMOSTEM, AERO SURF, CG100, SHP607, and several others.
  • Bronchopulmonary Dysplasia Market Drivers and Barriers
  • Bronchopulmonary Dysplasia Market Access and Reimbursement

Table of Content

  1. Key Insights
  2. Executive Summary
  3. Competitive Intelligence Analysis
  4. Bronchopulmonary Dysplasia Market Overview at a Glance
  5. Bronchopulmonary Dysplasia Disease Background and Overview
  6. Patient Journey
  7. Epidemiology and Patient Population
  8. Bronchopulmonary Dysplasia Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Treatment
  11. Bronchopulmonary Dysplasia Marketed Products
  12. Bronchopulmonary Dysplasia Emerging Therapies
  13. Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Bronchopulmonary Dysplasia Market Outlook
  16. Access and Reimbursement Overview
  17. KOL Views
  18. Bronchopulmonary Dysplasia Market Drivers
  19. Bronchopulmonary Dysplasia Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

Get to know more information about the market share of Bronchopulmonary Dysplasia treatment therapies @ Bronchopulmonary Dysplasia Market Companies

You may explore our latest Pharmaceutical Market Research Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: [email protected]
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

By krehani

Leave a Reply

Your email address will not be published. Required fields are marked *